[Jopamidol, a non-ionic x-ray contrast medium--tolerance from a neurological viewpoint]

Area of Science:

• Radiology
• Medical Imaging
• Contrast Media

Background:

• Contrast media are essential for diagnostic imaging procedures.
• Meglumine iodamine has been a widely used contrast agent.
• Evaluating newer, potentially safer contrast agents is crucial.

Purpose of the Study:

• To compare the efficacy and safety of jopamidol with meglumine iodamine.
• To assess radiograph quality in cranial computed tomography (CT) and cerebral angiography.
• To evaluate patient tolerance and side effect profiles of the two contrast media.

Main Methods:

• A double-blind, comparative trial involving 80 patients.
• 40 patients underwent cranial CT, and 40 underwent cerebral angiography.
• Jopamidol and meglumine iodamine were administered and outcomes assessed.

Main Results:

• No significant difference in radiograph quality was observed between jopamidol and meglumine iodamine.
• Jopamidol demonstrated significantly better patient tolerance.
• Fewer side effects and complications were reported with jopamidol compared to meglumine iodamine.

Conclusions:

• Jopamidol offers comparable diagnostic imaging quality to meglumine iodamine.
• Jopamidol presents a superior safety and tolerability profile.
• Jopamidol is a promising alternative contrast medium for cranial CT and cerebral angiography.